BioMosaics

BioMosaics is a biotechnology company specializing in the development and commercialization of advanced diagnostic biomarkers for liver cancer. The company is best known for its work on the AFP-L3 and Des-gamma-carboxy prothrombin (DCP) tests, which provide significantly higher specificity than total AFP for the early detection of hepatocellular carcinoma (HCC). Now operating as a subsidiary of FUJIFILM Wako Pure Chemical Corporation, BioMosaics' technologies are integrated into the μTASWako i30 immunoanalyzer platform. Their biomarkers are also core components of the GALAD score, a validated risk-assessment model used to identify HCC in patients with chronic liver disease. The company's products are FDA-cleared and widely utilized in clinical practice to improve surveillance and outcomes for high-risk liver patients.